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Introducing one or more intramolecular thioether bridges in a peptide provides a
promising approach to create more stable molecules with improved pharmacodynamic
properties and especially to protect peptides against proteolytic degradation.
Lanthipeptides are compounds that naturally possess thioether bonds in their structure.
The model lanthipeptide, nisin, is produced by Lactococcus lactis as a core peptide
fused to a leader peptide. The modification machinery responsible for nisin production,
including the Ser/Thr-dehydratase NisB and the cyclase NisC, can be applied for
introducing a thioether bridge into peptides fused to the nisin leader peptide, e.g., to
replace a disulfide bond. Vasopressin plays a key role in water homeostasis in the
human body and helps to constrict blood vessels. There are two cysteine residues in the
structure of wild type vasopressin, which form a disulfide bridge in the mature peptide.
Here, we show it is possible to direct the biosynthesis of vasopressin variants in such a
way that the disulfide bridge is replaced by a thioether bridge using the nisin modification
machinery NisBTC, albeit at low efficiency. Vasopressin mutants were fused either to the
nisin leader peptide directly (Type A), after the first three rings of nisin (Type B/C), or after
full nisin (Type D). The type B strategy was optimal for expression. LC-MS/MS data
verified the formation of a thioether bridge, which provides proof of principle for this
modification in vasopressin. This is a first step prior to the necessary increase of the
production yield and further purification of these peptides to finally test their biological
activity in tissue and animal models.
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INTRODUCTION
Vasopressin, a neurohypophysial hormone, was originally detected by Oliver and Schäfer (1895),
who demonstrated that extracts of the pituitary gland altered blood pressure. Subsequently,
vasopressin was isolated and its properties were further investigated (Vigneaud, 1952). Mammalian
vasopressin was reported to be produced primarily within the hypothalamic area and then released
or projected to various brain regions in response to stress, sexual stimulation, uterine dilatation,
and dehydration (Donaldson and Young, 2008; Insel, 2010). Vasopressin is used in medicine for
different treatments including diabetes insipidus, vasodilatory shock, and gastrointestinal bleeding.
The half-life of vasopressin is 16–24 min (Czaczkes et al., 1964; Baumann and Dingman, 1976),
similarly to other peptide hormones (de Vries et al., 2010).
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It has been reported that cyclization of therapeutic peptides is
a successful method to produce peptide analogs with improved
stability and biological properties (Kluskens et al., 2009; Takatsuji
et al., 2019). Cyclization can impose conformational constrains
and then either enhance or compromise the interaction with
their receptors to some extent (Rew et al., 2002). There are
also other ways to stabilize peptides by modification, e.g.,
by construction of N-methyl-peptide libraries or by making
backbone-cyclic peptides retaining their C-terminal peptide
regions via side chain thioether covalent linkages (Kawakami
et al., 2008; Takatsuji et al., 2019). However, intramolecular
thioether bridge insertion has been applied on peptides
like angiotensin, somatostatin, and glycoprotein D rendering
molecules with higher potency (Kluskens et al., 2009). In
addition, thioether bridges can render peptide analogs more
stable when compared to their linear form or disulfide bond-
cyclized counterparts due to the higher stability of the thioether
linkage against oxidation and proteolysis compared to the
disulfide bond (Tugyi et al., 2005). Therefore, we aimed at
replacing a disulfide bond by a thioether to extend the half-
life of vasopressin.
The chemical synthesis of thioether bridged peptides can be
costly and time-consuming, whereas the biological synthesis of
these peptides is often more straightforward and amenable to
mutational studies (Koeller and Wong, 2001; Kluskens et al.,
2005; Guzmán et al., 2007; van Heel et al., 2013; Montalbán-
López et al., 2017). Lanthipeptides are ribosomally produced
peptides containing lanthionine. The specific modification
and secretion machinery of nisin, a paradigm lanthipeptide,
produced by Lactococcus lactis, includes NisB, NisC, and NisT.
Nisin is first produced as a fusion of a leader peptide and
a core peptide, where the leader peptide is recognized by
NisB, NisC, and NisT (Lubelski et al., 2008). Serine and
threonine residues in the core peptide can be dehydrated
by the dehydratase NisB to become dehydroalanines (Dha)
or dehydrobutyrines (Dhb), respectively. Dehydrated serine or
threonine residues can then be regio- and stereo-specifically
coupled to a cysteine by the cyclase NisC. The modified
peptide is transported out of the cell via the ABC-transporter
NisT. Notably, NisB, NisC, and NisT have a relaxed substrate
specificity and various peptides fused to the nisin leader
peptide can be efficiently modified (Lubelski et al., 2008).
Engineering of this biosynthesis machinery rendered a two-
plasmid platform (Supplementary Figure S1) where the
modification enzymes and transport protein are expressed
from a pIL253-derivative and the engineered leader-containing
peptides are encoded on a pNZ8048-derivative, both under
the control of a nisin-inducible promoter (Rink et al., 2005).
This enables easy manipulation and controlled expression of
peptides of interest, either related to lantibiotic sequences, or
unrelated ones (Lubelski et al., 2008; Montalbán-López et al.,
2017). It has been successfully applied to diverse peptides
attached to the nisin leader peptide such as angiotensin,
diverse lantibiotics identified using genome mining, and nisin
fusions to antimicrobial peptides active against Gram-negative
bacteria (Kluskens et al., 2009; van Heel et al., 2016; Li
et al., 2018). All these could be expressed in the culture
supernatants, purified and activated upon removal of the
nisin leader peptide.
Due to the interest in vasopressin and other similar peptide
hormones such as oxytocin, and the feasibility of using the
nisin modification machinery to replace the disulfide bridge
by lanthionine, we designed several mutants that could render
mature, thioether-stabilized vasopressin, replacing a Cys by a
Ser in such a way that the serine residue can be dehydrated by
NisB, and then coupled to the thiol group of the cysteine via the
cyclase NisC to form a thioether bridge. In several constructs,
the production of thioether-containing vasopressin was indeed
detected and characterized. However, further optimization
of the yield of the modified peptide will be required to
be able to characterize the stability and bioactivity of the
modified peptide.
MATERIALS AND METHODS
Bacterial Strains, Plasmids, and
Chemicals
The bacterial strains and vectors used in this work are listed
in Table 1. L. lactis was used for expression of the modified
peptides and cultured in M17 broth supplemented with 0.5%
(w/v) glucose (GM17) or GM17 agar for genetic manipulation
or in minimal expression medium (MEM) (Rink et al., 2005) for
protein expression at 30◦C.
Chloramphenicol and/or erythromycin were used at 5 µg/mL
when appropriate.
The plasmids pNZnisA-E3 (Kuipers et al., 2004) and pNZnisA
leader6H were used for the expression of nisin and as a template
for the construction of the designed hybrid peptides. Plasmids
pIL3BTC (Rink et al., 2005) and pIL3EryBTC (van Heel et al.,
2013) encoding the nisin modification machinery were used to
produce and modify the fusion peptides.
Commercial vasopressin [(Arg8)-Vasopressin acetate salt] was
ordered from Sigma-Aldrich as a control. Endoproteinase Glu-
C from Staphylococcus aureus V8 (V8), cyanogen bromide
(CNBr), hydroxylamine (NH2OH), 3-Bromo-3-methyl-2-(2-
nitrophenylthio)-3H-indole (BNPS-Skatole), and trypsin were
ordered from Sigma-Aldrich as cleavage reagents. Ammonium
acetate (CH3COONH4), formic acid, guanidine hydrochloride
(Gdn-HCl), and lactic acid were ordered from Sigma-Aldrich. All
the chemical reagents are of analytic purity.
Construction of Expression Vectors
The vectors harboring different coding sequences for nisin and
vasopressin hybrid peptides, listed in Table 1, were obtained
by round PCR as described previously (Li et al., 2018). Fast
digest restriction enzymes and ligase were supplied by Thermo-
Fischer and used according to the manufacturer’s instructions.
In order to introduce a thioether ring into vasopressin, the
amino acid sequence was changed from “CYFQNCPRG” into
“SYFQNCPRG” (Figure 1). The primers (Supplementary Table
S1) were designed according to the new sequences and insert
the vasopressin sequence between the nisin part and the
restriction site HindIII. Notably, different protease/chemical
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TABLE 1 | Strains and plasmids used in this work.
Strains or plasmids Characteristics Purpose References
Strains
L. lactis NZ9000 pepN::nisRK Expression host and indicator strain Kuipers et al., 1997
Vectors
pNZnisA-E3 EryR, nisA Nisin expression Kuipers et al., 2004
pNZnisA leader6H CmR, nisA, encoding nisin, with
6-his residues inserted behind
the first methionine
Expression vector, expression of a 6-his tagged
nisin
Zhou et al., 2016
pNZE3 empty EryR Expression vector van Heel et al., 2013
pNZ8048 CmR Expression vector Kuipers et al., 1997
pIL3BTC CmR, nisBTC, under the
control of PnisA
Modification and transport of lantibiotics Rink et al., 2005
pIL3EryBTC EryR, nisBTC, under the control
of PnisA
Modification and transport of lantibiotics van Heel et al., 2013
pNZE-nisleader-G-VSP EryR, G-SYFQNCPRG Expression of vasopressin, with a glycine in
front of vasopressin
This work
pNZE-nisleader-ASPRG-VSP EryR, ASPRG-SYFQNCPRG Expression of vasopressin, with “ASPRG” in
front of vasopressin
This work
pNZE-nisleader-NG-VSP EryR, NG-SYFQNCPRG Expression of vasopressin, with asparagine and
glycine in front of vasopressin
This work
pNZE-nisleader-MG-VSP EryR, MG-SYFQNCPRG Expression of vasopressin, with methionine and
glycine in front of vasopressin
This work
pNZE-nisleader-WG-VSP EryR, WG-SYFQNCPRG Expression of vasopressin, with tryptophan and
glycine in front of vasopressin
This work
pNZE-nisleader-EG-VSP EryR, EG-SYFQNCPRG Expression of vasopressin, with glutamic acid














Expression of hybrid peptide, with asparagine




Expression of hybrid peptide, with methionine




Expression of hybrid peptide, with tryptophan




Expression of hybrid peptide, with glutamic acid




Expression of hybrid peptide, with asparagine




Expression of hybrid peptide, with methionine
and glycine in front of vasopressin
This work
pNZ-nisA-NG-VSP CmR, nisA, NG-SYFQNCPRG Expression of hybrid peptide, with asparagine
and glycine in front of vasopressin
This work
pNZ-nisA-MG-VSP CmR, nisA, MG-SYFQNCPRG Expression of hybrid peptide, with methionine
and glycine in front of vasopressin
This work
CmR, chloramphenicol resistance; EryR, erythromycin resistance.
cleavage sites were included in front of the vasopressin part
(Table 2). Each pair of primers contained a part annealing
with the template vector pNZnisA-E3 or pNZnisA leader6H,
and a part encoding vasopressin. First, we made pNZ-nisA-
NG-VSP and pNZ-nisA-MG-VSP, which include the whole
sequence of nisin A. These vectors served as a template to
construct all the other vectors containing the same cleavage
sites, which shared the same forward primers with each other,
and a variable reverse primer depending on the length of
the nisin part to be fused to [e.g., primer named “EG-VSP-
fwd” can be used as forward primers for both pNZE-nis(123-
34)-EG-VSP and pNZE-nisleader-MG-VSP]. This round PCR
strategy served for both pNZ-nisA-E3 and pNZnisA leader6H
derivatives. The constructions of expression plasmids can be
divided into three different types, according to the part of
nisin harbored in the plasmids (Figure 1). The part on
nisin preceding the vasopressin was expected to increase
the processivity of the modification enzymes giving them
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FIGURE 1 | Organization of hybrid peptides. The yellow box corresponds to the mutant vasopressin of which the first cysteine was changed to serine to form a
thioether bridge between dehydrated serine and cysteine with the nisin machinery. A glycine is in the front of the vasopressin sequence after cleavage of the nisin
moiety. The putative thioether bridge is labeled in red. 6H-leader means that there are six histidine at the N-terminus of the nisin leader sequence. (A) pNZE-derived
vectors harboring nisin leader and vasopressin hybrid genes. (B) pNZE-derived vectors harboring (A–C) rings of nisin and vasopressin hybrid genes. (C) pNZnisA
leader6H-derived vectors harboring (A–C) rings of nisin and vasopressin hybrid genes. (D) pNZnisA leader6H-derived vectors harboring nisin and vasopressin hybrid
genes.
TABLE 2 | Cleavage methods.
Preferred sequence cleaved Sample conditions used References
Protease cleavage
-K-↓-G-Vsp Trypsin in 5 mM CaCl2 and 50 mM Tris, pH 6.0, 37◦C, overnight Mu et al., 2015
-ASPR-↓-G-Vsp NisP in 50 mM CH3COONH4, pH 6.0, 37◦C, overnight Li et al., 2018
-E-↓-G-Vsp a ratio of 1:20 (w/w) of V8 to substrate, 50 mM NH4HCO3, pH 7.8, 37◦C, overnight Toews et al., 2010
Chemical cleavage
-N-↓-G-Vsp 1 M NH2OH+6 M Gdn-HCl, pH 9.0, 45◦C, 2∼3 h Park et al., 2001; Hwang et al., 2014
-M-↓-G-Vsp 100 mM CNBr in 70% formic acid, room temperature, overnight Kaiser and Metzka, 1999; Hwang et al., 2014
-W-↓-G-Vsp 10 mM BNPS-skatole, 80% acetic acid, 47◦C, 1 h Rahali and Gueguen, 1999; Hwang et al., 2014
a “head” start and thus enhance good modification of the
vasopressin part too.
After amplification, the cleaned-up PCR products were
digested using DpnI to remove the template and ligated over-
night. The ligation product was desalted and transformed into
L. lactis NZ9000 according to standard procedures (Holo and
Nes, 1995), isolated, extracted using a commercial plasmids
extraction kit (Macherey-Nagel), and the integrity of the sequence
was verified by DNA sequencing (Macrogen).
Protein Expression and Purification
Each vector containing the mutant structural gene, either derived
from pNZnisA-E3, or pNZnisA leader6H, was transformed into
NZ9000 (pIL3BTC) or NZ9000 (pIL3EryBTC), respectively. Cells
were first cultured overnight in GM17 medium with 5 µg/mL
chloramphenicol and 5 µg/mL erythromycin and transferred into
MEM medium (Rink et al., 2005) at a final concentration of 2%.
Nisin was added as inducer for expression (Kuipers et al., 1995; Li
et al., 2018). 5 ng/mL nisin was added twice, first at the beginning
of the inoculation and then at the time when the culture reached
an OD (600 nm) of 0.4–0.6. Thus, after the second addition of
nisin, the final concentration of nisin was 10 ng/mL, still below
the MIC value, thus subinhibitory.
Cells were harvested 3 h after the second induction by
centrifugation at 4◦C for 20 min at 6500 rpm and the supernatant
was filtered and kept for the isolation of fusion peptides.
In order to detect the designed peptides rapidly, a small
volume of culture supernatant was used for precipitation using
trichloroacetic acid (TCA) according to Sambrook and Russell
(2001). The concentrated secreted fusion peptides were analyzed
on a 16% Tricine SDS-PAGE gel (Schägger and von Jagow, 1987;
Schägger, 2006) and stained with Coomassie blue (Fermentas).
Precipitation experiments were performed at least in triplicate.
Alternatively, when higher amounts of peptides were required,
a larger volume (≥1 L) of culture was inoculated, centrifuged, and
concentrated by fast flow cationic exchange chromatography and
gel filtration. The cell-free supernatant was mixed at a ratio 1:1
with a 100 mM lactic acid solution and applied to a 5 mL HiTrap
SP-Sepharose (GE Healthcare) column previously equilibrated
with 50 mM lactic acid pH 4.0. Bound peptides were washed with
50 mM lactic acid solution pH 4.0 and eluted with 50 mM lactic
acid, 1 M NaCl pH 4.0 (Lubelski et al., 2009). Subsequently, a
PD-10 desalting column (GE Healthcare) was used to desalt the
samples following the manufacturer’s instructions. The desalted
samples were freeze-dried afterward.
The peptides were purified to homogeneity by reversed-phase
high performance liquid chromatography (RP-HPLC). Solvents
used for RP-HPLC were solvent A (0.1% TFA in MilliQ water)
and solvent B (0.1% TFA in acetonitrile). The fusion peptides
were purified with a C12 column [4 µm proteo 90 Å column,
250∗ 4.6 mm (Phenomenex)], as indicated elsewhere (Zhou et al.,
2015). Meanwhile, the peptides after digestion were purified with
a C18 column [3.6 µm Aeris peptide 100 Å column, 250∗ 4.6 mm
(Phenomenex)]. Following a 10 min washing step with 5% solvent
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B, a gradient of 15–30% of solvent B over 30 min was executed at
a flow rate of 1 mL/min. Peptides were detected measuring the
absorbance at 226 nm. The fractions were collected and analyzed
by mass spectrometry (van Heel et al., 2013). The active and pure
fraction was lyophilized and stored as a powder until further use.
Cleavage of Fusion Peptides
The fusion peptides were treated with the protease NisP,
trypsin or endoprotease Glu-C, or site-specific chemical reagents
to remove the nisin part. NisP was purified by affinity
chromatography using a Ni-NTA fast flow resin (Qiagen)
as described elsewhere (Montalbán-López et al., 2018). The
chemical reagents needed harsher conditions (e.g., CNBr in 70%
formic acid) than the cited proteases. The cleavage methods and
conditions used are listed in Table 2.
MALDI-TOF Mass Spectrometry and
Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS)
A total of 1 µL TCA-precipitated sample or HPLC-purified
fraction was loaded on the target and dried. Washing with Milli-
Q water was needed if the sample was a TCA precipitation
experiment. Subsequently, 1 µL of matrix solution was spotted
on the washed sample. The matrix solution consisted of
5 mg/mL α-cyano-4-hydroxycinnamic acid dissolved in 50%
(v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid. A Voyager
DE PRO matrix-assisted laser desorption ionization time-of-
flight (MALDI-TOF) mass spectrometer (Applied Biosystems)
was used to obtain mass spectra using conditions previously
established (van Heel et al., 2013). Data were analyzed with “Data
Explorer” software version 4.0.0.0 (Applied Biosystems).
After digestion with either one of the chemicals (CNBr,
NH2OH, and BNPS-Skatole) or proteases (NisP, trypsin, and V8)
the proteolytic mix was applied to an Ultimate 3000 nano-LC-
MS/MS system (Dionex) in line connected to an LTQ Orbitrap
XL mass spectrometer (Thermo Fisher Scientific) as previously
reported (Mu et al., 2015). The peptides were monitored by MS
through 100–2000 m/z, and its molecular weight determined
(Mu et al., 2015).
RESULTS
Design and Expression of Fusion
Peptides
The sequence of wild-type vasopressin “CYFQNCPRG-NH2” is
constrained by a disulfide bridge between the two Cys residues.
In order to make this peptide amenable for the nisin modification
machinery, the first Cys was mutated into Ser, generating the
sequence “SYFQNCPRG.” This vasopressin mutated sequence
was fused at the end of either full nisin or truncations thereof
(Figure 1), inserting in each case a cleavage site for several
different peptidases and chemical reagents that can facilitate the
release of this hormone. Since the lanthionine ring can impose
a structural constraint that limits the cleavage rate, an extra Gly
residue was placed in all cases in front of the SYFQNCPRG
sequence. Thus, in type A mutants (Figure 1A), the fusion was
done directly to the leader peptide of nisin, whereas in type B the
first rings of nisin were still present. Similarly, in type C mutants
rings ABC of nisin were present, but an additional 6xHis in the
leader peptide had been inserted for easier purification. Last, type
D mutants consisted of vasopressin fused to full length nisin and
with a His-tag in the leader. Thus, nisin and the fusion peptides
containing a nisin moiety and vasopressin were produced by
the nisin inducible production system previously described,
which consists of NZ9000 (pIL3BTC, pNZE-nisin derivative) or
NZ9000 (pIL3EryBTC, pNZ-leader6H-nisin derivative) (Kuipers
et al., 2004; Rink et al., 2005; van Heel et al., 2013). In the
latter case, the presence of a polyhistidine tag in the leader
peptide enables purification by IMAC as well. The production
levels were monitored by TCA precipitation of the supernatants
and the peptides were detected by tricine SDS-PAGE. As shown
FIGURE 2 | Production of vasopressin-nisin hybrids monitored by
coomassie-blue stained Tricine SDS-PAGE. TCA precipitated supernatants of
L. lactis NZ9000 (pIL3BTC, pNZE-nisin derivative) or NZ9000 (pIL3EryBTC,
pNZ-nisin derivative) were loaded in each well. Marker, molecular weight
marker; Wild-type nisin band produced using the same vector system as a
positive control is marked by an arrow. (A) Type A vasopressin mutants fused
to the nisin leader peptide (i.e., pNZE-nisleader-VSP mutants), positive
control, NZ9000 (pNZnisA-E3, pIL3BTC); negative control, NZ9000 (pNZE3
empty, pIL3BTC). (B) Type B vasopressin mutants fused to rings ABC of nisin
[i.e., pNZE-nis(123-34)-VSP, positive control, NZ9000 (pNZnisA-E3,
pIL3BTC); negative control, NZ9000 (pNZE3 empty, pIL3BTC)]. Upper light
bands are most probably dimers by intermolecular disulfide formation, of
those molecules where a thioether was not formed.
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in Figure 2, the production levels of the mutants obtained
from the four different strategies varied greatly from each other
and this mainly depended on the nisin part harbored in the
vectors and the presence of the his-tag. Prepeptides formed
by derivatives of pNZnisA leader6H (Type C/D) contained
a his-tag, while type A and type B derivatives did not. The
pNZE-nisin derivatives containing rings ABC of nisin (Type B)
showed a higher production level, in a range similar to wild-
type nisin produced using the same system. However, there were
no detectable bands on the tricine SDS-PAGE gels of the TCA
samples from the pNZE-nisin derivatives containing only the
nisin leader peptide (Type A). Four pNZ-nisin derivatives with
either ring A, B, and C of nisin or full nisin (Type C/D) were also
checked (data not shown). pNZ-nis(123-34)-NG-VSP showed a
quite low production level and weak bands on the tricine SDS-
PAGE gel and the production of the other three variants [pNZ-
nis(123-34)-MG-VSP, pNZ-nisA-NG-VSP, and pNZ-nisA-MG-
VSP] could not be detected by tricine SDS-PAGE. The differences
in the production levels among type A, B, and C peptides might
be due either to the His-tags in the nisin leader peptide, or the
increased lengths of the peptide sequences or their effects on the
processivity of the modifying enzymes. The strains containing the
plasmids pIL3BTC and pNZE-nis(123-34)-VSP showed the best
production levels. So, only type B variants were further purified
and analyzed. We have found that most of the peptides were
secreted out of the cell and very limited amount of peptides were
present in the intracellular fraction.
Characterization of Purified Fusion
Peptides
All the type B fusion peptides were further purified via fast
flow cationic exchange chromatography at a larger scale. The
mass of the peptide variants before nisin part removal was
determined via MALDI-TOF to assess the modification extent
of the hybrid peptides, considering that a dehydration results
in a mass difference of −18 Da. The results of mass analyses
are listed in Table 3 and Supplementary Figure S2. For all
the type B peptides, the fully dehydrated hybrid peptides were
obtained in addition to partly dehydrated peptides, and we
observed that the different cleavage sites (amino acids between
the nisin part and vasopressin sequence) made no difference
with regard to the dehydration extent of peptides. This means
that, although there are molecules in which not all the serine
and threonine residues in the core peptide are dehydrated, there
is a large proportion of the peptide in which all the serine
and threonine residues are dehydrated, including the serine
present in the engineered vasopressin part. This dehydration
in vasopressin enables the formation of a thioether bond
with the cysteine residue present. However, to confirm the
formation of the thioether rings, additional experiments such as
MS/MS (see below) are needed since thioether formation results
in no mass change.
Cleavage and Characterization of
Cleaved Peptides
Fusion peptides harboring A, B, and C rings of nisin were cleaved
off according to the specific cleavage site (Table 2). The masses
of cleaved vasopressin were determined by MALDI-TOF and
MS/MS. The results of MALDI-TOF are listed in Table 3 and
Supplementary Figure S2.
After removal of the nisin moiety, vasopressin with the
sequence “GSYFQNCPRG” could be obtained from all of
the peptides. For all the structures, after digestion, both
dehydrated and non-dehydrated vasopressin were detected,
indicating partial dehydration and limited cyclization. Although
MALDI is not a quantitative technique, for the peptides
pNZE-nis(123-34)-ASPRG-VSP, pNZE-nis(123-34)-MG-VSP,
and pNZE-nis(123-34)-EG-VSP, the majority of the vasopressin
released corresponded to dehydrated peptide, whereas in the
remaining cases the peak corresponding to dehydrated VSP was
too low. The chemical utilized to cleave between “M” and “G” is
CNBr. CNBr is a toxic pseudohalogen (Kohn and Wilchek, 1984),
thus, for large scale purification, preferably pNZE-nis(123-34)-
ASPRG-VSP, pNZE-nis(123-34)-EG-VSP were used (could be
TABLE 3 | MS analysis and yields of type B peptides before and after nisin part removal considering the highest dehydration number possible.
Name Predicted mass (Da) Measured mass (Da) Observed dehydrations/total possible dehydrations Yield (µg/L)
Full length type B fusion peptides
pNZE-nis(123-34)-G-VSP 5562.71 5560.97 6/6 660
pNZE-nis(123-34)-ASPRG-VSP 5955.94 5955.60 7/7 570
pNZE- nis(123-34)-EG-VSP 5691.76 5691.56 6/6 760
pNZE- nis(123-34)-NG-VSP 5676.75 5676.39 6/6 530
pNZE- nis(123-34)-MG-VSP 5693.75 5693.35 6/6 620
pNZE- nis(123-34)-WG-VSP 5748.79 5748.39 6/6 610
Vasopressin released after cleavage of type B peptides
pNZE-nis(123-34)-G-VSP 1110.21 1112.68 1/1 30
pNZE-nis(123-34)-ASPRG-VSP 1110.21 1111.89 1/1 10
pNZE- nis(123-34)-EG-VSP 1110.21 1111.63 1/1 100
pNZE- nis(123-34)-NG-VSP 1110.21 1111.44 1/1 38
pNZE- nis(123-34)-MG-VSP 1110.21 1110.91 1/1 54
pNZE- nis(123-34)-WG-VSP 1110.21 1111.87 1/1 36
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cleaved by NisP or V8, respectively) and analyzed by HPLC and
LC-MS/MS analysis.
Cleaved products of pNZE-nis(123-34)-ASPRG-VSP and
pNZE-nis(123-34)-EG-VSP were loaded on an analytical
C18 column for better separation, and purified via HPLC.
Commercial vasopressin (with the sequence “CYFQNCPRG”)
was used as a control (Figure 3). The commercial vasopressin and
engineered vasopressin can be eluted at around 22% of solvent B.
Firstly, we analyzed NisP-treated pNZE-nis(123-34)-ASPRG-
VSP. The cleavage site of NisP is after proline-arginine, similarly,
to the last part of vasopressin, so the last amino acid (glycine)
of the vasopressin part might also be cut off. Thus, different
vasopressin parts after digestion with or without the C-terminal
glycine could be detected as shown by mass spectrometry. After
HPLC separation, the peaks still contained a residual part of
not fully dehydrated vasopressin (Figure 3A) with or without
the last glycine. The injected amount of commercial vasopressin
was 6 µg, and thus, we can estimate by comparison of the
peak areas that the amounts of peak 1, 2, 3, and 4 were 0.28,
0.23, 0.25, and 2.3 µg, respectively. The yield of the dehydrated
vasopressin from the original culture was around 10 µg/L, which
was extremely low.
For pNZE-nis(123-34)-EG-VSP, when a C18 column was
used, four peaks were collected (Figure 3B) and most of
them were non-dehydrated forms, except peak 1, which proved
to be a pure dehydrated vasopressin part (Figure 3B). The
amount of peptide from peak 1 was around 0.8 µg, and
the yield from the original culture was around 100 µg/L,
which was still not enough for further tests including stability,
pharmacokinetic/pharmacodynamic tests, and animal tests.
LC-MS/MS Fragments Analysis
Previous MALDI-TOF results clarified the dehydration of serine
in the vasopressin part in pNZE-nis(123-34)-ASPRG-VSP and
pNZE-nis(123-34)-EG-VSP. However, more tests were needed
to check if the thioether bridges were formed since there is no
mass difference derived from the thioether formation. Therefore,
we repeated the digestion of the peptides and the mix was
subjected to LC/MS setting an appropriate mass window for
the ion trap according to previous experiments that showed
the double charged ion as the most abundant species in these
conditions (data not shown). Vasopressin parts of both pNZE-
nis(123-34)-ASPRG-VSP and pNZE-nis(123-34)-EG-VSP were
first detected with LC/MS and then further isolated for MS/MS
fragmentation (Figure 4). In this experimental setup, the chances
to get fragmentation at the level of the peptide bond are
higher than those to break the thioether bond. Therefore,
if a lanthionine ring (i.e., thioether) is formed, fragments
connecting the N- and the C-terminus of vasopressin but
lacking amino acids encompassed in the lanthionine ring could
be detected. Dehydrated vasopressin, with the m/z = 555.74
for the double charged ion, could be observed with a RT
around 8 min [RT = 8.28 for pNZE-nis(123-34)-ASPRG-VSP
and RT = 8.26 for pNZE-nis(123-34)-EG-VSP] and further
fragmented (Supplementary Figure S3). According to the LC-
MS/MS results, a fragment containing Dha can be found in
both samples. Remarkably, peaks consistent with three specific
fragments (DhaCPRG, GDhaYFNCP, and GDhaYNCPR) were
detected in the vasopressin part of pNZE-nis(123-34)-EG-
VSP. If we assume that the thioether ring is formed, there
would be both a thioether bridge connecting Cys and Dha
and peptide bonds linking the amino acids between Dha
and cysteine (Figure 1). During the fragmentation process
in MS/MS determination, either of the peptide bonds can
be broken, and the three specific fragments depicted above
can only occur if the peptide bonds are broken and the
more stable thioether bridge remained (Figure 4B). In this
case, one or more amino acids between Dha and cysteine
which are connected via peptide bonds might be lost, while
the thioether bridge can still connect Dha, and cysteine with
the Dha and cysteine bound to the other amino acids left
via peptide bonds.
Thus, we can conclude that, for the fusion peptides containing
the ABC rings of nisin, not all the vasopressin moieties were
dehydrated. In addition, the dehydrated peptide can be either
linear or cyclic with a thioether bridge. Specific fragments were
found in the vasopressin part of pNZE-nis(123-34)-EG-VSP,
which showed the formation of a thioether ring in the peptide.
Thus, we conclude that at least part of the molecules have the
expected length and contain a thioether bridge.
DISCUSSION
It has been reported that rapid breakdown has limited the
efficacy of many therapeutic peptides in complex biological fluids
(de Vries et al., 2010). Cyclization can impose conformational
constrains and then provide protection against proteolytic
degradation as well as stabilize the conformation suitable for
receptor binding (Bosma et al., 2019). Notably, a thioether
link is more stable than a disulfide bond against hydrolytic
decomposition, oxidation, or human serum (Tugyi et al.,
2005; Rink et al., 2007). Biosynthesis would ideally allow to
rapidly obtain different variants to discover improved analogs
of vasopressin. Due to the interest of vasopressin and related
peptide hormones (e.g., oxytocin) and the stabilizing effect of
cyclization, in our work, a thioether bridge was introduced into
vasopressin using the nisin modification machinery in order to
create improved and more stable vasopressin variants.
Engineering of vasopressin should take into account the
design and working principles of the nisin modification
machinery. It has been described that, in spite of its promiscuity,
NisBTC cannot equally well modify any peptide sequence fused
to the nisin leader peptide (Kuipers et al., 2008) and that
it can more efficiently modify peptides attached to the first
rings of nisin (van Heel et al., 2016; Li et al., 2018; Schmitt
et al., 2019). NisT is a broad substrate transporter that can
effectively export lantibiotics but also unmodified peptides of
variable length (Kuipers et al., 2004; Bosma et al., 2011). Since
NisB and NisC modify from N- to C-terminus (Lubelski et al.,
2009) minimally the first cysteine in the sequence of vasopressin
needs to be replaced by serine to provide a dehydratable residue
for NisB and thereby a substrate for a thiol attack from the
remaining cysteine that renders the thioether bond. The peptide
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FIGURE 3 | HPLC chromatograms and MALDI-TOF results of peaks collected after enzymatic cleavage of the vasopressin mutants.
(A) pNZE-nis(123-34)-ASPRG-VSP separated using a C18 column. (B) pNZE-nis(123-34)-EG-VSP separated using C18 column. Commercial vasopressin was
used as a standard and is depicted in blue line whereas the red chromatogram corresponds to the cleaved nisin-vasopressin hybrid. The mass of the peaks
corresponding to vasopressin is attached to the chromatogram. For the mass spectra of collected peaks, different color correspond to different mass. Red,∼1110
Da, corresponds to the sequence of “GDhaYFQNCPRG”; yellow,∼1129 Da, corresponds to the sequence of “GSYFQNCPRG”; green,∼1054 Da, corresponds to
the sequence of “GDhaYFQNCPR” with dehydrated serine; blue,∼1072 Da, correspond to the sequence of “GSYFQNCPR.” Dha, dehydroalanine
(i.e., dehydrated serine).
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FIGURE 4 | MS/MS results of characteristic fragments. (A) MS/MS fragments of 7 characteristic fragments labeled as green (correspond to linear vasopressin) or
blue (correspond to the fragment can be either linear vasopressin or cyclized vasopressin). (B) MS/MS fragments of 11 characteristic fragments labeled as green
(correspond to linear vasopressin), red (cyclized vasopressin), or blue (correspond to the fragment can be either linear vasopressin or cyclized vasopressin). Dha,
dehydroalanine; red line between Dha and cysteine indicates a thioether bridge.
sequence surrounding the dehydratable residue is also key for
modification and residues present in the cleavage site play a
role. Moreover, since the presence of unusual amino acids such
as Dha and the formation of the thioether bond between Dha
and Cys in vasopressin could prevent cleavage, an extra Gly
was always placed between the engineered cleavage site and the
vasopressin sequence. The presence of N-terminal amino acids or
other chemical substituents in vasopressin sequence has rendered
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active molecules such as terlipressin, with three glycines in this
position, which is marketed for clinical use (Dobre et al., 2011;
Wang et al., 2018). Thus, the presence of glycine or other amino
acids at this position is tolerated in terms of activity and enables
easier cleavage.
Taking into account the requirements of the nisin
modification machinery exposed above we designed different
groups of peptides in order to achieve the highest peptide yield.
Since intracellular peptides are always incompletely modified
and prone to be degraded, we only focused on the extracellular
fraction. The type B peptides, with ABC rings of nisin, followed
by Gly-vasopressin were proven to be optimal for production and
independently of the cleavage sequence (Figure 2 and Table 3).
This is in line with previous data indicating a better modification
of non-cognate peptides when the N-terminus of wild-type nisin
is present due to better binding to NisB (Mavaro et al., 2011;
van Heel et al., 2016). Due to the higher yields and the easier
and safer cleavage, the nisin part was removed with appropriate
proteases (V8 or NisP) from pNZE-nis(123-34)-ASPRG-VSP
and pNZE-nis(123-34)-EG-VSP.
After cleavage, most of the products were still a mixture
of non-dehydrated and dehydrated vasopressin parts either
cyclized or not, indicating that the sequence of vasopressin
is not optimal for NisB and NisC. NisBC naturally render a
mix of differently dehydrated peptides during nisin production
and particularly when non-cognate peptides are used (Lubelski
et al., 2008; van Heel et al., 2016) and that is also the
case in these vasopressin mutants. It has been reported that
some medically relevant non-lantibiotic peptides, including
angiotensin, erythropoietin mimetic and enkephalin, were not
fully dehydrated in the presence of NisB (Kluskens et al.,
2005). Moreover, NisC was found to show preference and
exclusion for particular amino acids at the flanking position
of cysteine (Rink et al., 2007). Nevertheless, we could obtain
a peptide from the strain harboring pNZE-nis(123-34)-EG-
VSP (Figure 3) whose mass was consistent with a thioether
stabilized vasopressin albeit at very low concentration (100 µg/L).
The tolerance to mutations and natural heterogeneity in other
lantibiotic biosynthesis clusters in literature similarly, shows
that, although the enzymes produce one main product, partly
modified peptides still appear. The modification of C-terminal
tails added to a truncated lacticin 481 variant induced impaired
dehydration by the enzyme LctM (Zhang and van der Donk,
2007). Even ProcM, which can naturally modify up to 29
lantibiotics generates byproducts that are not fully modified
(Li et al., 2010). Moreover, the alteration of the core peptide
induces wrong modification patterns or leaves free cysteines as
observed with NukM (Shioya et al., 2010). In fact, the sequence
of the core peptide (and not only the leader peptide) has an
enormous influence in the modification pattern observed with
type II lantibiotic modification enzymes (Thibodeaux et al., 2014;
Tang et al., 2016). The analysis of a large library of lantibiotic
mutants that kept the first two rings of nisin/gallidermin also
demonstrated that although NisBTC is a very suitable screening
system, when they face non-cognate peptides heterogeneity and
low production constitute a burden for high yield production
(Schmitt et al., 2019).
MS/MS experiments unambiguously show three characteristic
fragments after cleavage that prove the presence of the thioether
Surprisingly, the increased length in the hinge region of nisin that
is imposed by the ASPR cleavage sequence in pNZE-nis(123-
34)-ASPR-VSP construct allows Dha formation in engineered
vasopressin but apparently reduces the cyclization efficiency
by NisC since no specific fragment consistent with thioether
formation was detected (Figure 4A).
Our work reports a biological way to introduce a thioether
bridge in vasopressin, albeit at low efficiency, and yield. An
improvement of the production yield of the peptide is essential
and thus this system still requires further improvement (more
efficient dehydration and cyclization) to meet the demands for
further physical and chemical tests as well as tissue models and
animal tests. Directed evolution of NisB and NisC enzymes for
hard-to-modify substrates is ongoing.
Some possibilities are the engineering of Ala1 instead of Gly1
and the replacement of Ser2 by Thr2 in the vasopressin sequence
to assess whether the modifications will be more efficient and
the yields improved. Hydrophobic, non-aromatic amino acids
are also considered to be direct flanking of dehydratable serine
or threonine to enhance the dehydratase activity (Rink et al.,
2005). Moreover, although it is not essential for the activities of
vasopressin, the C-terminal amidoglycine could be chemically
installed after purification (Zou et al., 2002). Alternatively, a
completely different enzymatic machinery could be employed,
such as the published ProcM (Mukherjee and van der Donk,
2014) or the yet unpublished SyncM (Arias Orozco and Kuipers,
manuscript in preparation). A next study will address these
possibilities to increase the yield of fully modified vasopressin
with a thioether bond.
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